<DOC>
	<DOC>NCT00038662</DOC>
	<brief_summary>The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective).</brief_summary>
	<brief_title>Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>prostate adenocarcinoma, radical prostatectomy, PSA between 0.4 and 5 ng/mL, PSADT &lt; 1 year previous hormonal therapy, salvage therapy to the pelvis within 3 months prior to randomization</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>